

**PROSCA'25**

Global Forum on  
Prostate Cancer


**PROGRAMME BOOKLET**

# Global Forum on Prostate Cancer

5-6 December 2025

EPIC SANA Lisboa Hotel, Portugal

[gu-global-forum.org](http://gu-global-forum.org)



# Welcome

## Dear colleagues, dear friends,

Congratulations, you've made it to Lisbon, the destination of your PROSCA journey! Some say the journey is more important than the destination. We say: they are equally important. The journey with the patient case challenges was the ideal warm-up for the real workout: PROSCA 2025.

This year, our focus remains on identifying the impact that new data and treatments have on best practice, and how to translate these into your daily clinical practice in order to improve patient management.

To achieve this, we have brought together an international multidisciplinary top faculty to present the data, along with a panel of experts who will shape these data into recommendations on the spot, in a discussion-based format where you will also have a voice!

Yes, in only one and a half days, you will:

- **get a full update on prostate cancer**
- **learn from keynote speakers about the major clinical advances for your practice**
- **get the chance to interact and challenge the expert panel during case discussions**
- **share a coffee and your views with top leaders**

Join the discussions and participate in the lively discussions! Ready, set, go!

## Welcome to Lisbon!

Share your photos  
and thoughts on X  
@mirrorsmed  
#PROSCA25



# Global organising committee



**V rane Achard**  
Radiation Oncology  
Bordeaux, France and  
Geneva, Switzerland



**Bertrand Tombal**  
Urology  
Brussels, Belgium



**Amit Bahl**  
Clinical Oncology  
Bristol, UK

---

## Local organising committee



**Lu s Costa / Raquel Br s**  
Medical Oncology  
Lisbon, Portugal



**Carla Lopes de Castro**  
Radiation Oncology  
Porto, Portugal



**Arnaldo Figueiredo**  
Urology  
Coimbra, Portugal



**Kris Maes**  
Urology  
Lisbon, Portugal



**M rio Fontes-Sousa**  
Medical Oncology  
Lisbon, Portugal



**Jos  Lu s Passos  
Coelho / Joana Duarte  
Albuquerque**  
Medical Oncology  
Lisbon, Portugal

# Faculty

**Vérane Achard**

Radiation Oncology  
Bordeaux, France and  
Geneva, Switzerland

**Amit Bahl**

Clinical Oncology  
Bristol, UK

**Raquel Brás**

Medical Oncology  
Lisbon, Portugal

**Eva Compérat (virtual)**

Pathology  
Vienna, Austria

**Luis Costa**

Medical Oncology  
Lisbon, Portugal

**Alan Dal Pra (virtual)**

Radiation Oncology  
Miami, USA

**Maria De Santis**

Medical Oncology  
Berlin, Germany

**Mário Fontes-Sousa**

Medical Oncology  
Lisbon, Portugal

**Valérie Fonteyne**

Radiation Oncology  
Ghent, Belgium

**Silke Gillesssen**

Medical Oncology  
Bellinzona, Switzerland

**Karolien Goffin**

Nuclear Medicine  
Leuven, Belgium

**Petros Grivas**

Medical Oncology  
Seattle, USA

**Peter Hoskin**

Clinical Oncology  
Northwood & Manchester &  
London, UK

**Rob Jones**

Medical Oncology  
Glasgow, UK

**Badrinath Konety**

Urology  
Minneapolis, USA

**Carla Lopes de Castro**

Radiation Oncology  
Porto, Portugal

**Kris Maes**

Urology  
Lisbon, Portugal

**David Olmos**

Medical Oncology  
Madrid, Spain

**Aurelius Omlin**

Medical Oncology  
Zürich, Switzerland

**Henning Plage**

Urology  
Berlin, Germany

**Daniele Raggi**

Medical Oncology  
London, UK

**Jayne Tierney**

Researcher  
London, UK

**Derya Tilki**

Urology  
Hamburg, Germany

**Bertrand Tombal**

Urology  
Brussels, Belgium

**Léa Turpin**

Nuclear Medicine  
Suresnes, France

**Julien Van Damme**

Urology  
Brussels, Belgium

**Roderick van den Bergh**

Urology  
Rotterdam, The Netherlands

**Inge van Oort (virtual)**

Urology  
Groningen, The Netherlands

**Nuno Vau**

Medical Oncology  
Lisbon, Portugal

**Ursula Vogl**

Medical Oncology  
Bellinzona, Switzerland

**Jochen Walz**

Urology  
Marseille, France

**Thomas Zilli**

Radiation Oncology  
Bellinzona, Switzerland



# Friday 5 December

09:15	<b>Industry-sponsored satellite symposium</b>
10:15	<b>Break</b>
11:00	<b>Official opening</b> Luís Costa, Carla Lopes de Castro
11:15	<b>Unfavourable intermediate- and high-risk PCa</b> Moderators: V��rane Achard, Carla Lopes de Castro  Treatment challenges in clinical practice: What do you tell your patients? - Peter Hoskin, Jochen Walz  Treatment strategies for elderly with locally advanced PCa - Bertrand Tombal  Genomic classifiers: PCa risk redefined? - Alan Dal Pra (live remote)  Panel discussion and Q&A
12:30	<b>Update lecture: Precision strategies in mHSPC: State of the art and future directions</b> Moderator: M��rio Fontes-Sousa  Optimising outcomes in mHSPC: Current treatment approaches - Nuno Vau  Genomic insights and emerging therapies in mHSPC - David Olmos  Discussion and Q&A
13:00	<b>Lunch</b>
14:00	<b>Case discussion session: Biochemical recurrence</b> Moderators: Roderick van den Bergh, Jochen Walz Panel: V��rane Achard, Carla Lopes de Castro, Val��rie Fonteyne, Peter Hoskin, Derya Tilki, Bertrand Tombal, Julien Van Damme, Roderick van den Bergh, Inge van Oort, Jochen Walz  Mirrors of Medicine – case-based approach - Bertrand Tombal  Case presentation - Raquel Br��s, Henning Pl��ge  Defining, imaging and managing BCR - Derya Tilki  PSA-only monitoring in BCR: Who qualifies? - Julien Van Damme  Optimising treatment in high-risk BCR patients - V��rane Achard  Panel discussion and Q&A

# Friday 5 December

15:30	<b>Update lecture: Balancing margins and potency recovery in PCa surgery</b> Moderator: Julien Van Damme Presenter: Kris Maes
16:00	<b>Break</b>
16:30	<b>Case discussion session: mHSPC</b> Moderators: Maria De Santis, Ursula Vogl Panel: Amit Bahl, Luís Costa, Maria De Santis, David Olmos, Aurelius Omlin, Daniele Raggi, Bertrand Tombal, Julien Van Damme, Roderick van den Bergh, Ursula Vogl, Thomas Zilli  Case presentation - Raquel Brás, Henning Plage  mHSPC – who needs radiotherapy? - Thomas Zilli  mHSPC – who needs treatment intensification? - Daniele Raggi  Treatment de-escalation in mHSPC - Bertrand Tombal  The STOPCAP M1 Initiative: How systematic reviews can influence patient management - Jayne Tierney  How to approach an mHSPC patient: Insights from clinical practice - Amit Bahl  Panel discussion and Q&A
18:05	<b>End of day 1 &amp; reception</b>



# Saturday 6 December

<b>08:25</b>	<b>Opening day 2</b>
<b>08:30</b>	<b>Case discussion session: CRPC</b> Moderators: Luís Costa, Rob Jones Panel: Amit Bahl, Raquel Brás, Luís Costa, Mário Fontes-Sousa, Silke Gillessen, Rob Jones, David Olmos, Aurelius Omlin, Inge van Oort, Ursula Vogl  Case presentation - Raquel Brás, Henning Plage  Combination approaches in first-line CRPC - Bertrand Tombal  Targeting CRPC with PARPi & immunotherapy - Aurelius Omlin  Targeting CRPC with radioligands - Karolien Goffin  Sequential approaches with ARPI and chemotherapy in CRPC - Amit Bahl  Patient-centred care in CRPC - Ursula Vogl  Panel discussion and Q&A
<b>10:05</b>	<b>Update lecture: Will AI replace the physician in PCa treatment?</b> Moderator: Jochen Walz Presenter: Badrinath Konety
<b>10:30</b>	<b>Break</b>
<b>11:00</b>	<b>Update lecture: Molecular diagnostics in motion: Liquid biopsies and tissue testing in mCRPC</b> Moderator: Derya Tilki Presenter: David Olmos
<b>11:30</b>	<b>APCCC Diagnostics 2025 highlights</b> Moderators: Silke Gillessen, Aurelius Omlin Panel: Derya Tilki, Bertrand Tombal, Léa Turpin, Thomas Zilli  Introduction - Silke Gillessen, Aurelius Omlin  Discussion on APCCC Diagnostics 2025 questions
<b>12:30</b>	<b>Lunch</b>
<b>13:30</b>	<b>Update lecture: The future of radioligands in PCa</b> Moderator: Karolien Goffin Presenter: Léa Turpin Panel case discussion: Karolien Goffin, Bertrand Tombal, Léa Turpin

# Saturday 6 December

14:10

## Looking ahead: PCa management in 2026

Moderator: Petros Grivas

View of the urologist - Roderick van den Bergh

View of the radiation oncologist - Thomas Zilli

View of the medical oncologist - Rob Jones

View of the pathologist - Eva Compérat (pre-recorded)

Discussion and Q&A

15:00

End of PROSCA



# Check out our unique and free CME programmes in oncology

Translating new data from key congresses and  
peer-reviewed papers into clinical practice



## Interactive CME

The case-based Mirrors of Medicine™ learning method is highly interactive and integrates scientific evidence and clinical expertise to appropriately apply new insights in clinical practice in a time-efficient manner. Our programmes focus on actual clinical topics where new evidence is having a major impact on best practice.



## Faculty

Our programmes are selected and defined by international experts involved in clinical decision making based on educational needs in a specific disease area.



## Online & in-person

To cater to individual learning preferences, both online (PinPoint Case Platform) as virtual (Abstract2Practice, Manuscript2Practice, webinars) or in-person (EACCME-accredited Global Forum) learning opportunities are available.



## Oncology

Our oncology programmes mainly focus on bladder, breast and prostate cancer, and renal cell carcinoma.



Why not join your colleagues...it's free!

[mirrorsmed.org](https://mirrorsmed.org)



# Certificate of attendance

- 1 Go to **<https://library.mirrorsmed.org>** and log in using your personal credentials you received by email.
- 2 Go to the section **“My certificates”** and **download** your certificate of attendance.

# Certificate of accreditation

- 1 Go to **<https://library.mirrorsmed.org>** and log in using your personal credentials you received by email.
- 2 Go to the section **“My certificates”** and complete the PROSCA **evaluation form**.
- 3 After completion, you can **download** your certificate of accreditation.
- 4 Deadline to complete the evaluation form and download the certificate of accreditation: **31 May 2026**.



Go to **<https://library.mirrorsmed.org>**

**X**  
Spread  
the word  
**@mirrorsmed**  
**#PROSCA25**

# Practical information



## Onsite contacts

<b>General information</b>	Delphine Corsten	+32 497 75 14 51
<b>Exhibitors &amp; sponsors</b>	Luc Van Ruysevelt	+32 476 25 82 94



## Opening hours registration & information desk

Thursday 4 December 2025:	07:30-18:00
Friday 5 December 2025:	07:30-18:00
Saturday 6 December 2025:	07:30-14:00

# Accreditation points



## **PROSCA 2025 - Global Forum on Prostate Cancer (13<sup>th</sup> edition), Lisbon & hybrid, Portugal 05/12/2025-06/12/2025,**

has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) with **10.0** European

CME credits (ECMEC®).

Accreditation Statement: Each medical specialist should claim only those credits that he/she actually spent in the educational activity. Through an agreement between the European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the process to convert EACCME® credits to AMA credits can be found at <https://edhub.ama-assn.org/pages/applications>. Live educational activities occurring outside of Canada, recognised by the UEMS-EACCME® for ECMEC® credits are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.

# PROSCA thanks its sponsors and partners

## Principal sponsor

---



## Platinum & educational sponsors

---



Johnson&Johnson

## Silver sponsor

---



## Silver sponsor & educational sponsor

---



## Bronze sponsor

---



## Bronze & educational sponsor

---




## Partners


---



Organised by  **ISSECAM**

Meeting  
management by 

 **Mirrors  
of medicine**



# Navigating ADT Choices in Prostate Cancer: A Patient-Centric Approach

**Friday 5 December 2025**

9:15 am - 10:15 am, Auditorium

Join interactive  
polling and  
discussion

## Faculty



*Chairman*  
**Bertrand Tombal**  
Brussels, Belgium



**Barbara Alicja  
Jereczek-Fossa**  
Milan, Italy



**Rob Jones**  
Glasgow, UK



**Aurelius Omlin**  
Zurich, Switzerland

## Agenda

### Introduction

*Prof. Bertrand Tombal*

### James' Complaints: A prostate cancer patient with severe LUTS

*Prof. Barbara Alicja Jereczek-Fossa*

### James' Dilemma: What is the optimal duration of combined endocrine therapy?

*Dr. Aurelius Omlin*

### James' Journey: Navigating ADT after a heart attack

*Prof. Rob Jones*


### Panel discussion & conclusion


*Moderated by Prof. Bertrand Tombal*

This promotional symposium is organised  
and sponsored by Accord Healthcare Ltd.

**accord**


Full invitation  
with speaker  
biographies





Together, we're  
*working tirelessly*  
to get in front  
of cancer...

...and create  
a future  
where *cures*  
*are a reality.*



Find out more on the  
**Johnson & Johnson**  
Medical Cloud

**Johnson  
& Johnson**

© 2025 Janssen Pharmaceutica NV.  
Janssen Pharmaceutica NV, a Johnson  
& Johnson company. Turnhoutseweg 30,  
B-2340 Beerse, Belgium.

EM-191658 | October 2025

accord


**ORGOVYX®** ▽  
(relugolix) 120 mg tablets

Rapid, sustained, surge free testosterone suppression<sup>1</sup>

# One & Only oral ADT<sup>®</sup>


Introducing ORGOVYX<sup>®</sup> the One & Only oral ADT for advanced hormone sensitive prostate cancer.<sup>2,3</sup>

Achieve rapid, sustained and surge free testosterone suppression.<sup>1</sup>




▽ This medication is subject to additional monitoring, reporting suspected adverse events associated with this medication is a priority.

ORGOVYX<sup>®</sup> is indicated for the treatment of adult patients with advanced hormone-sensitive prostate cancer.<sup>2</sup>



Scan the QR code for the ORGOVYX<sup>®</sup> EU PI.



Scan the QR code for the ORGOVYX<sup>®</sup> UK PI.

Adverse events should be reported. For UK HCPs, reporting forms and information can be found at [www.mhra.gov.uk/yellowcard](http://www.mhra.gov.uk/yellowcard). Adverse events should also be reported to Accord LTD on +44 (0)1271 385 257 or email [medinfo@accord-healthcare.com](mailto:medinfo@accord-healthcare.com). For non-UK/EU HCPs, you can also report side effects directly via the national reporting system listed in Appendix V of the EU SmPC.

This material was created by Accord Healthcare Ltd. and is intended for Healthcare Professionals only.

\*ADT, androgen deprivation therapy; EU, European Union; HCP, healthcare professional; PI, prescribing information; QR, quick response; SmPC, Summary of Product Characteristics; UK, United Kingdom.

1. Shore ND, Saad F, Cookson MS, *et al.* *N Engl J Med.* 2020;382(4):2187–2196. 2. ORGOVYX<sup>®</sup> Summary of Product Characteristics. 3. Fragkoulis C, *et al.* *Arab J Urol.* 2021;19(4):460–463.

EUR-Onc-Org-01636 | October 2025



# ***Helping patients*** *create lasting memories*

Looking forward to seeing you  
***at the Bayer booth***

**SAVE THE DATE**

# Translating new data into clinical practice

## Highlights of 2026

**2-5 December 2026**

Amsterdam, The Netherlands

### **RENALC'26**

Global Forum on  
Renal Cancer

### **BLADDR'26**

Global Forum on  
Bladder Cancer

### **PROSCA'26**

Global Forum on  
Prostate Cancer





# ***Helping patients*** *create lasting memories*

Looking forward to seeing you  
***at the Bayer booth***

# Notes

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....



# Notes

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

# Notes

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

.....

**PROSCA'25**

Global Forum on  
Prostate Cancer

# ALL SESSIONS ARE INTERACTIVE



## ASK QUESTIONS & ANSWER POLLS VIA YOUR SMARTPHONE

Ask the faculty all your questions and participate in interactive voting via your smartphone.

**JOIN AT  
SLIDO.COM  
#PROSCA**

**OR SCAN**



**WE LOOK FORWARD TO HEARING YOUR OPINION!**